Effect of availability of oral iron chelation therapy (ICT) on initiation, duration, and dose adequacy in patients with myelodysplastic syndromes (MDS) and transfusional iron overload (TIO).
Steven Gore
Research Funding - Celgene; GlaxoSmithKline; Novartis
Amy J. Davidoff
Research Funding - Celgene; GlaxoSmithKline; Novartis
Franklin Hendrick
No relevant relationships to disclose
Vu Duong
No relevant relationships to disclose
Bruce C. Stuart
No relevant relationships to disclose
Maria R. Baer
Research Funding - Celgene; GlaxoSmithKline; Novartis
Rahul Shenolikar
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Amer Zeidan
No relevant relationships to disclose